North America Cancer Biomarker Market Size & Outlook
The cancer biomarker market in North America is expected to reach a projected revenue of US$ 25,589.3 million by 2033. A compound annual growth rate of 11% is expected of North America cancer biomarker market from 2026 to 2033.
- Clinical Diagnostics
- In Vitro Diagnostics
- Cancer Biomarker Market Outlook
- In Vitro Diagnostics
Revenue, 2025 (US$M)
$11,201.8
Estimate, 2026 (US$M)
$12,353.9
Forecast, 2033 (US$M)
$25,589.3
CAGR, 2026 - 2033
11.0%
Global Market
Related Markets
Prism AI by Grand View ResearchFree to try
Ask a question about the cancer biomarker market
Every figure cited from GVR research
North America cancer biomarker market highlights
- The North America cancer biomarker market generated a revenue of USD 11,201.8 million in 2025.
- The market is expected to grow at a CAGR of 11% from 2026 to 2033.
- In terms of segment, lung cancer was the largest revenue generating type in 2025.
- Lung Cancer is the most lucrative type segment registering the fastest growth during the forecast period.
- Country-wise, Mexico is expected to register the highest CAGR from 2026 to 2033.
North America data book summary
| Market revenue in 2025 | USD 11,201.8 million |
| Market revenue in 2033 | USD 25,589.3 million |
| Growth rate | 11% (CAGR from 2026 to 2033) |
| Largest segment | Lung cancer |
| Fastest growing segment | Lung Cancer |
| Historical data covered | 2021 - 2024 |
| Base year for estimation | 2025 |
| Forecast period covered | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Breast Cancer, Prostate Cancer, Colorectal Cancer, Cervical Cancer, Liver Cancer, Lung Cancer |
Other key industry trends
- In terms of revenue, North America region accounted for 41.6% of the global cancer biomarker market in 2025.
- Globally, North America is projected to lead the regional market in terms of revenue in 2033.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 18,028.2 million by 2033.
No credit card required*
Publish Date: May 11, 2026
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cancer Biomarker Market Scope
Cancer Biomarker Market segmentation & scope
Cancer Biomarker Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Merck KGaA | View profile | 62,345 | Frankfurter Strasse 250, Darmstadt, HE, Germany, 64293 | www.emdgroup.com |
| Thermo Fisher Scientific Inc | View profile | 122,000 | 168 Third Avenue, Waltham, MA, United States, 02451 | www.thermofisher.com |
| Illumina Inc | View profile | 9,300 | 5200 Illumina Way, San Diego, CA, United States, 92122 | www.illumina.com |
| Agilent Technologies Inc | View profile | 17,700 | 5301 Stevens Creek Boulevard, Santa Clara, CA, United States, 95051 | www.agilent.com |
| Qiagen NV | View profile | 5,900 | Hulsterweg 82, Venlo, LI, Netherlands, 5912 PL | www.qiagen.com |
| Hologic Inc | View profile | 6,990 | 250 Campus Drive, Marlborough, MA, United States, 01752 | www.hologic.com |
| CanSino Biologics Inc Class H | View profile | 1,494 | 185 South Avenue, 401-420, 4th Floor, Biomedical Park, TEDA West District, Tianjin, China, People's Republic of, | www.cansinotech.com |
| F. Hoffmann-La Roche Ltd. | View profile | - | - | - |
| Abbott | View profile | - | - | - |
North America Cancer Biomarker Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Cancer Biomarker Market Outlook will help companies and investors design strategic landscapes.
Lung Cancer was the largest segment with a revenue share of 24.28% in 2025.
Horizon Databook has segmented the North America cancer biomarker market based on breast cancer, prostate cancer, colorectal cancer, cervical cancer, liver cancer, lung cancer covering the revenue growth of each sub-segment from 2021 to 2033.
- North America Cancer Biomarker Market Type Outlook (Revenue, USD Million , 2021-2033)
- Breast Cancer
- Prostate Cancer
- Colorectal Cancer
- Cervical Cancer
- Liver Cancer
- Lung Cancer
- Others
- North America Cancer Biomarker Market Biomolecule Outlook (Revenue, USD Million , 2021-2033)
- Genetic Biomarkers
- Epigenetic Biomarkers
- Metabolic Biomarkers
- Proteomic Biomarkers
- North America Cancer Biomarker Market Application Outlook (Revenue, USD Million , 2021-2033)
- Drug Discovery and Development
- Diagnostics
- Personalized Medicine
- North America Cancer Biomarker Market Technology Outlook (Revenue, USD Million , 2021-2033)
- Polymerase Chain Reaction (PCR)-based Technologies
- Next-Generation Sequencing (NGS)-based Technologies
- Immunoassay-based Technologies
- In Situ Hybridization (ISH) & Cytogenetic Technologies
- Mass Spectrometry-based Technologies
- Imaging-based Biomarker Technologies
Reasons to subscribe to Cancer Biomarker Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Cancer Biomarker Market Outlook databook
- Our clientele includes a mix of Cancer Biomarker Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America Cancer Biomarker Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into North America Cancer Biomarker Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
North America Cancer Biomarker Market, 2021-2033 (US$M)
North America Type - Cancer Biomarker Market Statistics, 2025 - 2033 (US$M)
